Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

IDEXX Laboratories, Inc. - Common Stock (NQ: IDXX )

444.53 -15.23 (-3.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about IDEXX Laboratories, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Idexx Labs Stock Rocketed Higher This Week
Via The Motley Fool
Exploring the top movers within the S&P500 index during today's session.
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday. 
Via Chartmill
Top S&P500 movers in Monday's session
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Stocks Trim Losses On Mexico Tariff Delay, Gold Extends Records, Tesla Sinks 6%: What's Driving Markets Monday?
Wall Street bounced back after President Donald Trump and Mexican President Claudia Sheinbaum agreed to a one-month suspension of tariffs following Mexico's pledge to bolster its military presence at... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Assessing IDEXX Laboratories: Insights From 4 Financial Analysts
Via Benzinga
(IDXX) - Analyzing IDEXX Laboratories's Short Interest
Via Benzinga
IDEXX Laboratories Posts Upbeat Results, Joins Stratasys, Saia And Other Big Stocks Moving Higher On Monday
Via Benzinga
Idexx Laboratories Barks Up A Beat, And Shares Jump To A Four-Month High
The company sells diagnostic equipment for veterinarians. Fourth-quarter metrics grew and beat expectations. 
Via Investor's Business Daily
Why Is Pet Health Company IDEXX Laboratories Stock Trading Higher On Monday?
Idexx Laboratories posted strong Q4 earnings, beating estimates with 10% EPS growth. 2025 guidance reflects up to 7% revenue growth and $1.5 billion in buybacks. 
Via Benzinga
Idexx: Q4 EPS, Revenue Beat Forecast
Idexx Laboratories exceeded earnings expectations for Q4 2024, buoyed by robust performance in its key diagnostic segments. 
Via The Motley Fool
Earnings Scheduled For February 3, 2025
Via Benzinga
(IDXX) - Analyzing IDEXX Laboratories's Short Interest
Via Benzinga
These S&P500 stocks have an unusual volume in today's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
Morgan Stanley Reveals Top 20 AI-Driven Stocks as Adoption Hits Critical Mass
Katy Huberty, the Global Head of Research at Morgan Stanley, has spotlighted 20 stocks from companies that are likely to see significant benefits from the adoption of Artificial Intelligence (AI). 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A 'Great Stock'
Via Benzinga
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
A Glimpse Into The Expert Outlook On IDEXX Laboratories Through 5 Analysts
Via Benzinga
Decoding 5 Analyst Evaluations For IDEXX Laboratories
Via Benzinga
A Once-in-a-Decade Opportunity: 2 Magnificent S&P 500 Stocks Down 37% and 28% to Buy Before 2025
Via The Motley Fool
Topics Stocks
Exposures US Equities
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today. 
Via The Motley Fool
A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback
Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,600 Today
Via Benzinga
Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth
Idexx Laboratories posted a Q3 EPS of $2.79, beating estimates, though revenue of $975.54 million fell short. Veterinary trends and guidance update key 2024 outlook. 
Via Benzinga
What Analysts Are Saying About IDEXX Laboratories Stock
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today
Via Benzinga
$100 Invested In IDEXX Laboratories 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 10 Years
Via Benzinga
Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 15 Years
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $800 Today
Via Benzinga
Animal Health Firm Idexx's Robust Business Model Bolsters Position Despite Slower Growth, Says Analyst
Idexx Laboratories reported a 15% rise in Q2 adjusted EPS to $3.02, surpassing the $2.88 consensus. Sales hit $1 billion, up 6%, with Companion Animal Group and Water revenue growth leading. Gross... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.